- Home
- LCTX vs LCW Comparison
LCTX vs LCW Comparison
Compare LCTX & LCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- LCW
- Stock Information
- Founded
- LCTX 1990
- LCW 2021
- Country
- LCTX United States
- LCW United States
- Employees
- LCTX N/A
- LCW N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- LCW Blank Checks
- Sector
- LCTX Health Care
- LCW Finance
- Exchange
- LCTX Nasdaq
- LCW Nasdaq
- Market Cap
- LCTX 165.6M
- LCW 165.8M
- IPO Year
- LCTX N/A
- LCW 2021
- Fundamental
- Price
- LCTX $0.89
- LCW $10.99
- Analyst Decision
- LCTX Strong Buy
- LCW
- Analyst Count
- LCTX 3
- LCW 0
- Target Price
- LCTX $5.67
- LCW N/A
- AVG Volume (30 Days)
- LCTX 327.9K
- LCW 55.0K
- Earning Date
- LCTX 11-07-2024
- LCW 01-01-0001
- Dividend Yield
- LCTX N/A
- LCW N/A
- EPS Growth
- LCTX N/A
- LCW N/A
- EPS
- LCTX N/A
- LCW N/A
- Revenue
- LCTX $6,186,000.00
- LCW N/A
- Revenue This Year
- LCTX N/A
- LCW N/A
- Revenue Next Year
- LCTX $119.00
- LCW N/A
- P/E Ratio
- LCTX N/A
- LCW N/A
- Revenue Growth
- LCTX N/A
- LCW N/A
- 52 Week Low
- LCTX $0.77
- LCW $10.60
- 52 Week High
- LCTX $1.61
- LCW $11.03
- Technical
- Relative Strength Index (RSI)
- LCTX 48.24
- LCW 50.58
- Support Level
- LCTX $0.83
- LCW $10.99
- Resistance Level
- LCTX $0.94
- LCW $11.01
- Average True Range (ATR)
- LCTX 0.05
- LCW 0.01
- MACD
- LCTX 0.00
- LCW -0.00
- Stochastic Oscillator
- LCTX 41.92
- LCW 50.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About LCW Learn CW Investment Corporation
Learn CW Investment Corp is a blank check company. It is formed for the purpose of effecting a merger, consolidation, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.